Steven Kelly
Chief Executive Officer bei CARISMA THERAPEUTICS, INC.
Vermögen: 1 118 $ am 30.04.2024
Aktive Positionen von Steven Kelly
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ARTELO BIOSCIENCES, INC. | Director/Board Member | 02.05.2017 | - |
| Independent Dir/Board Member | 02.05.2017 | - | |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 01.02.2018 | - |
| Chief Executive Officer | 01.02.2018 | - | |
| President | 01.02.2018 | - | |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Director/Board Member | 23.04.2018 | - |
| Chief Executive Officer | 23.04.2018 | - | |
| Founder | 23.04.2018 | - | |
| President | 23.04.2018 | - |
Karriereverlauf von Steven Kelly
Ehemalige bekannte Positionen von Steven Kelly
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Kelly Bioconsulting LLC
 Kelly Bioconsulting LLC Miscellaneous Commercial ServicesCommercial Services Kelly Bioconsulting LLC provides business consulting services. The private company is based in Boulder. | Corporate Officer/Principal | 01.01.2012 | 01.01.2018 |
Pinteon Therapeutics, Inc.
 Pinteon Therapeutics, Inc. BiotechnologyHealth Technology Pinteon Therapeutics, Inc. develops cancer and CNS therapeutics. It focuses on the discovery and development of therapeutics targeting Pin1. The firm specializes in aberrant disease processes and improves patient outcomes in medical need indications. The company is headquartered in Newton Centre, MA. | Chief Executive Officer | 01.04.2014 | 01.07.2015 |
| President | 01.04.2014 | 01.07.2015 | |
Theracrine, Inc.
 Theracrine, Inc. BiotechnologyHealth Technology Theracrine, Inc. develops anti-metastatic drugs for cancer therapeutics. It provides scientific and technological services as well as research and design relating thereto. The company was founded by David A. Berry, Noubar B. Afeyan, Robert A. Weinberg, Joan Massagué and Douglas Hanahan in 2006 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01.06.2011 | 01.08.2012 |
Innovive Pharmaceuticals, Inc.
 Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | President | 01.06.2004 | 11.10.2010 |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Corporate Officer/Principal | 02.07.2010 | - |
Ausbildung von Steven Kelly
| Cornell University | Masters Business Admin |
| University of Oregon | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 10 |
| 2 |
Operativ
| President | 4 |
| Chief Executive Officer | 4 |
| Director/Board Member | 3 |
Sektoral
| Health Technology | 7 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CARISMA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Health Technology |
Innovive Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | Health Technology |
Pinteon Therapeutics, Inc.
Pinteon Therapeutics, Inc. BiotechnologyHealth Technology Pinteon Therapeutics, Inc. develops cancer and CNS therapeutics. It focuses on the discovery and development of therapeutics targeting Pin1. The firm specializes in aberrant disease processes and improves patient outcomes in medical need indications. The company is headquartered in Newton Centre, MA. | Health Technology |
| Artelo Biosciences, Inc. | |
Theracrine, Inc.
Theracrine, Inc. BiotechnologyHealth Technology Theracrine, Inc. develops anti-metastatic drugs for cancer therapeutics. It provides scientific and technological services as well as research and design relating thereto. The company was founded by David A. Berry, Noubar B. Afeyan, Robert A. Weinberg, Joan Massagué and Douglas Hanahan in 2006 and is headquartered in Cambridge, MA. | Health Technology |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
Kelly Bioconsulting LLC
Kelly Bioconsulting LLC Miscellaneous Commercial ServicesCommercial Services Kelly Bioconsulting LLC provides business consulting services. The private company is based in Boulder. | Commercial Services |
- Börse
- Insiders
- Steven Kelly
- Erfahrung
